1. Home
  2. INSM vs KHC Comparison

INSM vs KHC Comparison

Compare INSM & KHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INSM
  • KHC
  • Stock Information
  • Founded
  • INSM 1988
  • KHC 1869
  • Country
  • INSM United States
  • KHC United States
  • Employees
  • INSM N/A
  • KHC N/A
  • Industry
  • INSM Biotechnology: Pharmaceutical Preparations
  • KHC Packaged Foods
  • Sector
  • INSM Health Care
  • KHC Consumer Staples
  • Exchange
  • INSM Nasdaq
  • KHC Nasdaq
  • Market Cap
  • INSM 29.0B
  • KHC 30.9B
  • IPO Year
  • INSM 2000
  • KHC N/A
  • Fundamental
  • Price
  • INSM $189.60
  • KHC $24.73
  • Analyst Decision
  • INSM Strong Buy
  • KHC Hold
  • Analyst Count
  • INSM 19
  • KHC 17
  • Target Price
  • INSM $171.12
  • KHC $27.41
  • AVG Volume (30 Days)
  • INSM 2.1M
  • KHC 15.7M
  • Earning Date
  • INSM 10-30-2025
  • KHC 10-29-2025
  • Dividend Yield
  • INSM N/A
  • KHC 6.47%
  • EPS Growth
  • INSM N/A
  • KHC N/A
  • EPS
  • INSM N/A
  • KHC N/A
  • Revenue
  • INSM $447,022,000.00
  • KHC $25,164,000,000.00
  • Revenue This Year
  • INSM $32.08
  • KHC N/A
  • Revenue Next Year
  • INSM $125.86
  • KHC $0.79
  • P/E Ratio
  • INSM N/A
  • KHC N/A
  • Revenue Growth
  • INSM 30.34
  • KHC N/A
  • 52 Week Low
  • INSM $60.40
  • KHC $24.10
  • 52 Week High
  • INSM $197.08
  • KHC $34.08
  • Technical
  • Relative Strength Index (RSI)
  • INSM 76.69
  • KHC 39.48
  • Support Level
  • INSM $154.79
  • KHC $24.10
  • Resistance Level
  • INSM $168.22
  • KHC $25.67
  • Average True Range (ATR)
  • INSM 6.44
  • KHC 0.50
  • MACD
  • INSM 1.81
  • KHC -0.03
  • Stochastic Oscillator
  • INSM 82.31
  • KHC 34.05

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

About KHC The Kraft Heinz Company

In July 2015, Kraft merged with Heinz to create one of North America's largest food and beverage manufacturers. However, the firm now intends to split its global sauces arm from its North American grocery segment in the second half of 2026. Beyond its namesake brands, its portfolio includes Oscar Mayer, Velveeta, and Philadelphia. While the retail channel drives around 85% of its total sales, the firm also maintains a growing foodservice presence. Outside North America, Kraft Heinz's global reach encompasses a distribution network in Europe and emerging markets, which accounts for nearly 25% of its consolidated sales base. The company's products are sold in more than 190 countries and territories.

Share on Social Networks: